Ovodan Biotech has a well-established network within academia. Therefore, our activities also include projects where we develop antibodies for research projects. The projects allow us to explore new areas of application and utilize new technologies in collaboration with true experts.
Currently, we are involved in project including diagnostics of COVID-19 and within IBD, Inflammatory Bowel Disease.
The pandemic virus SARS-CoV-2 requires no further presentation. Several vaccines have been developed and are rolled out, but variants of the SARS-CoV-2 WT seems to challenge diagnostics and the efficacy of the vaccines.
At Ovodan Biotech we are convinced that a faster, more specific, and reliable rapid test is needed on the market. And we strive to deliver the most potent antibodies for this purpose.
At Ovodan Biotech we have launched our chicken antibodies towards the SARS-CoV-2 Spike receptor binding domain (RBD). The binding coefficient is identified within the nanomolar-range which is within the range of monoclonal antibodies.
Please see the datasheet for the antibodies here >>
In addition, we have also expressed the spike receptor binding domain of the new corona virus. Initially for the immunization of chicken, but the RBD protein is also recognized by antibodies from previously infected individuals.
Please see the datasheet for the antigen here >>
The SARS-CoV-2 Spike RBD and the anti-SARS-CoV-2 chicken antibody are both available for your research activities and assay developments.
In collaboration with Aalborg University, Department of Chemistry and Bioscience we have also launched our new platform of nanobody development. The first nanobodies towards SARS-CoV-2 Spike RBD are under development and to be introduced within a few weeks.
IBD – inflammatory bowel disease – covers diseases as Ulcerative colitis and Crohn’s disease. More than 6 million patients are today diagnosed with IBD. The symptoms involve severe diarrhea, abdominal pain, fatigue and weight loss and it is likely to have periods of active illness followed by periods of remission.
Consequently, patients are supported by monitoring the level of the inflammation biomarker Calprotectin, a highly conserved mammal protein present at local inflammation sites. In the case of IBD also in fecal samples.
At Ovodan Biotech we have developed chicken polyclonal antibodies toward Calprotectin (MRP-14). As host chickens are the perfect choice since Calprotectin are considered highly conserved within mammal strains. Furthermore, the anti-MRP-14 IgY does not cross react with rheumatoid factors or mammalian Fc receptors.
Please find the datasheet here >>
We are closely following the research within this area to support patients and physicians to develop better and more specific diagnostic tools. And we are always open to dialogues about projects where we can contribute with our experience.
